Answers are grounded in this paper and cite their sources.
Tissue specimens remain the gold standard for diagnosis and molecular characterization of cancer, but their acquisition is invasive and often difficult to repeat, particularly in pediatric neuro-oncology. Liquid biopsies offer a minimally invasive approach for obtaining tumor-related information from accessible biofluids. Blood, including plasma and serum, is the most widely investigated matrix, while cerebrospinal fluid (CSF) is biologically closer to central nervous system (CNS) tumors and may provide a higher tumor-derived signal. Molecular profiling through liquid biopsies therefore has considerable potential to support precision medicine, longitudinal disease assessment, and treatment monitoring in children with brain tumors. Among circulating regulatory RNAs, canonical small RNAs include microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), and tRNA-derived small RNAs (tsRNAs), whereas circular RNAs (circRNAs) represent a structurally and size-distinct RNA class that can also be detected in biofluids. Current pediatric clinical evidence is strongest for circulating miRNAs, with studies supporting potential diagnostic, prognostic, disease-monitoring, and treatment-response assessment applications across several pediatric CNS tumor entities. In contrast, circulating piRNAs and tsRNAs remain largely supported by adult, mixed-age, or preclinical glioma studies and require dedicated validation in pediatric cohorts. Adult-derived findings remain valuable as hypothesis-generating translational evidence when pediatric data are unavailable, but should not be considered directly transferable without independent pediatric validation. Interpretation of circulating RNA signatures also requires consideration of their biological origin. Circulating RNAs may derive directly from tumor cells, but can also reflect immune and inflammatory responses, blood-cell or platelet contributions, treatment effects, and blood–brain or blood-tumor barrier permeability. Their detection in peripheral blood therefore cannot be attributed simply to small molecular size, and circulating profiles may not faithfully reproduce the tumor RNA landscape. Clinical translation further depends on rigorous control of pre-analytical and analytical variables, including biofluid selection, hemolysis, collection and processing procedures, storage, RNA isolation, normalization, and platform choice. Although small-RNA sequencing, RT-qPCR, and digital PCR provide complementary opportunities for discovery and validation, most circulating RNA biomarkers in pediatric brain tumors remain investigational. Prospective, multicenter validation in molecularly defined pediatric cohorts, standardized workflows, demonstration of analytical and clinical performance, and independent clinical utility assessment will be essential before these biomarkers can be integrated into routine patient management.
No takes yet. Share an insight, caveat, or question.
Dossena et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: